Spain’s competition watchdog has fined Italy-based drugmaker Leadiant Biosciences 10.3 million euros ($10.63 million) for selling an orphan drug at an excessive price, it said on Monday.
Related: Judge Curbs Reach Of Generic Drugmakers Antitrust Suit
